## ASSESSING PATIENT-REPORTED OUTCOMES AND PHARMACIST INTERVENTIONS IN PATIENTS PRESCRIBED SPECIALTY MEDICATIONS FOR DERMATOLOGY AND ASTHMA, SINUS, AND ALLERGY



**Number of Interventions** 

E. Danielle Bryan, PharmD<sup>1</sup> | Rebekah Finley, PharmD candidate<sup>2</sup> | Nisha B. Shah, PharmD<sup>1</sup> | Ryan Moore, MS<sup>3</sup> | Josh DeClercq, MS<sup>3</sup> | Leena Choi, PhD<sup>3</sup> | Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP<sup>1</sup>

1 Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center; Lipscomb University College of Pharmacy; Department of Biostatistics, Vanderbilt University Medical Center

## **RESULTS BACKGROUND DERMATOLOGY COHORT (N=144) ASAP COHORT (N=46)** Patient reported outcomes (PROs) can be used to assess therapeutic response and **TABLE 1. DERMATOLOGY PATIENT** FIGURE 2. ASAP DIAGNOSES AND TABLE 2. ASAP PATIENT FIGURE 1. DERMATOLOGY MEDICATIONS need for therapeutic changes in patients **CHARACTERISTICS MEDICATIONS CHARACTERISTICS** with dermatology, asthma, sinus, and Tofacitinib 1 n (%) n (%) allergy disease states.1 Age, years, median (IQR) 53 (40-63) Golimumab 1 Age, years, median 50 (41-62) Dupilumab (n=37) Gender, male 61 (42) (IQR) Vanderbilt Specialty Pharmacy, a health-Brodalumab 1 Race Gender, male 19 (41) system specialty pharmacy (HSSP), White 114 (79) Certolizumab **2** Race assesses PROs through monthly refill Mepolizumab (n=3) Black or African American 22 (15) White questionnaires (MRQs) to guide pharmacist 31 (67) Ustekinumab Moderate to severe Other Asian 4 (3) interventions and improve patient care.<sup>2</sup> Black or African asthma (n=43) 14 (30) Ixekizumab 4 (3) Unknown American Omalizumab (n=2) Insurance type Declined to answer **OBJECTIVE** 1 (2) Guselkumab Commercial 95 (66) To assess PROs in patients receiving **Insurance type** Bexarotene Medicare 44 (31) dermatology or asthma, sinus, and allergy Commercial 24 (52) Benralizumab (n=1) Medicaid 4 (3) Etanercept **10** (ASAP) medications at an HSSP Medicare 18 (39) Diagnosis Medicaid Secukinumab 4 (9) Primary humoral Immune globulin Plaque psoriasis 92 (64) **METHODS** immunodeficiency **Smoking status** (n=2)**Apremilast** 24 Atopic dermatitis 31 (22) (n=2)Non-smoker 30 (65) Hidradenitis suppurativa 12 (8) Dupilumab **DESIGN** Single-center retrospective Previous smoker 14 (30) Mycosis fungoides 5 (3) Chronic analysis Adalimumab Current smoker 35 2 (4) rhinosinusitis with 4 (3) Other Dupilumab (n=1) nasal polyposis **INCLUSION Previous biologic** Patients receiving a **Number of Patients** Previous biologic 27 (59) 57 (40) (n=1)dermatology or ASAP specialty therapy, yes therapy, yes 1: Pruritis medication with: 1: Constipation 2+ fills through the center's 4: illness specialty pharmacy, and Adverse 1: Nausea Missed Dupilumab: Adverse • 2+ MRQ responses effects Missed doses doses : Injection site effects hot flashes 2: memory bruising **TIMEFRAME** January - March 2020 FIGURE 4. SPECIALTY PHARMACIST INTERVENTIONS FOR DERMATOLOGY AND ASAP PATIENTS (N=29) FIGURE 3. OVERALL MEDICATION EFFECTIVENESS **OUTCOMES Coordination of care** ED / hospitalization / urgent care 99% (n=589) of 'How well do the MRQ you feel **Patient-reported Patient-reported** Condition-related concern or exacerbation responses rated medication is adverse effects missed doses medication working for effectiveness as **Medication list change** you?" 'excellent' or 'good' Common side effect / toxicity **597 MRQ**

## CONCLUSIONS

- Patients with inflammatory conditions receiving care within an integrated health system specialty pharmacy reported high medication effectiveness with low rates of missed doses (3.2%) and adverse effects (<1%).
- Specialty pharmacists perform valuable interventions to ensure safe and effective medication use. Further research is needed to understand the long-term clinical outcomes in these populations.

responses

**Patient-reported** 

medication

effectiveness

**Specialty** 

pharmacist

interventions

**General drug information** 

Adherence / missed dose